Stocks-FATE-Fate Therapeutics Inc

FATE Fate Therapeutics Inc

18.87 -0.23 (-1.20%)
in USD Market Open
Invest
Invest

Overview

Prev Close19.10
Day's Range 18.54 - 19.27
52 Week Range 17.08 - 66.45
Average Volume (3m)1.29M
1-Year Return-66.10%
Beta1.6353
Market Cap1.86B
P/E Ratio
Revenue69.01M
EPS-3.0465
Dividend (Yield)0 (0%)
1 Day 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years Max
Created with Highcharts 4.2.7 /Highstock 4.2.728/06/202209/09/202218/11/202220.0025.0030.0035.0040.00
Chart times in UTC
Industry Biotechnology
CEO J. Scott Wolchko
Employees 449

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2021: Fate Therapeutics Inc's revenues increased by 77.66% and amounted to 55.85M. Net income decreased by 22.36% to -212.15M. Net assets increased by 76.58% to 678.84M and EPS decreased from -2.10 to -2.24.
FATE's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
N/A
Net Profit Margin
-860.31%
Operating Margin
-454.06%
Return On Investment
-36.94%
12/21
03/22
06/22
09/22
Total Revenue
17.07M
18.41M
18.55M
14.98M
Gross Profit
N/A
N/A
15.59M
11.79M
Operating Income
-69.38M
N/A
-83.11M
-86.39M
Net Income
-68.62M
-65.69M
-76.11M
-83.56M